• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.04% Nasdaq Up0.27%

    Verastem, Inc. (VSTM)

    2.25 Up 0.06(2.51%) 3:57PM EST - Nasdaq Real Time Price
    ProfileGet Profile for:
    Verastem, Inc.
    117 Kendrick Street
    Suite 500
    Needham, MA 02494
    United States - Map
    Phone: 781-292-4200
    Website: http://www.verastem.com

    Index Membership:N/A
    Full Time Employees:47

    Business Summary 

    Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing proprietary small molecule drugs targeting cancer stem cells (CSCs). The company’s programs target the focal adhesion kinase (FAK) and the PI3K/mTOR signaling pathways. Its lead FAK inhibitor, VS-6063, is in a registration-directed trial in patients with malignant pleural mesothelioma; a Phase Ib trial in combination with weekly paclitaxel for patients with ovarian cancer; a Phase II study in patients with non-small cell lung cancer; and a Phase II trial preceding surgery in mesothelioma, as well as a combination trial of VS-6063 and VS-5584 in patients with relapsed mesothelioma. The company is also developing FAK inhibitor, VS-4718, and dual mTORC1/2 and PI3K inhibitor VS-5584 that are in Phase I clinical trials in patients with advanced cancers. Its product candidates target CSCs, which have been implicated in aggressive cancers, metastasis, and chemotherapeutic resistance. The company has license agreement with Whitehead Institute for Biomedical Research; The Scripps Research Institute; and Pfizer, Inc. Verastem, Inc. was founded in 2010 and is based in Needham, Massachusetts.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Verastem, Inc.

    Corporate Governance 
    Verastem, Inc.’s ISS Governance QuickScore as of Nov 1, 2015 is 7. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 8; Compensation: 7.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Robert Forrester LL.B., 51
    Chief Exec. Officer, Pres and Director
    Mr. Daniel W. Paterson , 54
    Chief Operating Officer
    Dr. Joanna C. Horobin M.B., Ch.B, 60
    Sr. Advisor
    Dr. Christoph H. Westphal M.D., Ph.D., 47
    Co-Founder and Exec. Chairman
    Mr. Richard H. Aldrich , 61
    Founder and Consultant
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders